Table Graph
      published meta-analysis   sensitivity analysis   studies

placebo in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsHYDRA (Hernandez-Cardenas), 2021 (REV) 1.25 [0.80; 1.94] 1.25[0.80; 1.94]HYDRA (Hernandez-Cardenas), 2021 (REV)10%214NAnot evaluable deathsdetailed resultsHYDRA (Hernandez-Cardenas), 2021 (REV) 1.25 [0.80; 1.94] 1.25[0.80; 1.94]HYDRA (Hernandez-Cardenas), 2021 (REV)10%214NAnot evaluable deaths (time to event analysis only)detailed resultsHYDRA (Hernandez-Cardenas), 2021 (REV) 1.25 [0.80; 1.94] 1.25[0.80; 1.94]HYDRA (Hernandez-Cardenas), 2021 (REV)10%214NAnot evaluable clinical improvement (time to event analysis only)detailed resultsHYDRA (Hernandez-Cardenas), 2021 (REV) 0.95 [0.68; 1.34] 0.95[0.68; 1.34]HYDRA (Hernandez-Cardenas), 2021 (REV)10%214NAnot evaluable hospital dischargedetailed resultsHYDRA (Hernandez-Cardenas), 2021 (REV) 0.99 [0.70; 1.40] 0.99[0.70; 1.40]HYDRA (Hernandez-Cardenas), 2021 (REV)10%214NAnot evaluable off oxygenationdetailed resultsHYDRA (Hernandez-Cardenas), 2021 (REV) 1.02 [0.66; 1.57] 1.02[0.66; 1.57]HYDRA (Hernandez-Cardenas), 2021 (REV)10%214NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-17 05:39 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 650 - roots T: 650

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons